Evidence map›Paper›PMID 33452090›Full record

ArticleJournal of the American Board of Family Medicine : JABFM

Perceptions of Patients with Primary Nonadherence to Statin Medications.

Derjung M Tarn, Maureen Barrientos, Mark J Pletcher, Keith Cox, Jon Turner, Alicia Fernandez, Janice B Schwartz

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Board of Family Medicine : JABFM. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Observational
  8. Not obtaining a medication the first time it is prescribed: primary non-adherence to cardiovascular pharmacotherapy.Clinical research in cardiology : official journal of the German Cardiac Society · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Derjung M TarnFrom the Department of Family Medicine, David Geffen School of Medicine at UCLA, University of California-Los Angeles, Los Angeles, CA (DMT); Divisions of Geriatrics and Clinical Pharmacology, Departments of Medicine and Bioengineering and Therapeutic Sciences, University of California-San Francisco, San Francisco, CA (MB, JBS); Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA (MJP); Department of Sociology, University of California-Los Angeles, Los Angeles, CA (KC); Department of Technology, Operations, and Statistics, Stern School of Business, New York University, New York, NY (JT); Department of Medicine, University of California-San Francisco, San Francisco, CA (AF).
Maureen BarrientosFrom the Department of Family Medicine, David Geffen School of Medicine at UCLA, University of California-Los Angeles, Los Angeles, CA (DMT); Divisions of Geriatrics and Clinical Pharmacology, Departments of Medicine and Bioengineering and Therapeutic Sciences, University of California-San Francisco, San Francisco, CA (MB, JBS); Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA (MJP); Department of Sociology, University of California-Los Angeles, Los Angeles, CA (KC); Department of Technology, Operations, and Statistics, Stern School of Business, New York University, New York, NY (JT); Department of Medicine, University of California-San Francisco, San Francisco, CA (AF).
Mark J PletcherFrom the Department of Family Medicine, David Geffen School of Medicine at UCLA, University of California-Los Angeles, Los Angeles, CA (DMT); Divisions of Geriatrics and Clinical Pharmacology, Departments of Medicine and Bioengineering and Therapeutic Sciences, University of California-San Francisco, San Francisco, CA (MB, JBS); Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA (MJP); Department of Sociology, University of California-Los Angeles, Los Angeles, CA (KC); Department of Technology, Operations, and Statistics, Stern School of Business, New York University, New York, NY (JT); Department of Medicine, University of California-San Francisco, San Francisco, CA (AF).
Keith CoxFrom the Department of Family Medicine, David Geffen School of Medicine at UCLA, University of California-Los Angeles, Los Angeles, CA (DMT); Divisions of Geriatrics and Clinical Pharmacology, Departments of Medicine and Bioengineering and Therapeutic Sciences, University of California-San Francisco, San Francisco, CA (MB, JBS); Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA (MJP); Department of Sociology, University of California-Los Angeles, Los Angeles, CA (KC); Department of Technology, Operations, and Statistics, Stern School of Business, New York University, New York, NY (JT); Department of Medicine, University of California-San Francisco, San Francisco, CA (AF).
Jon TurnerFrom the Department of Family Medicine, David Geffen School of Medicine at UCLA, University of California-Los Angeles, Los Angeles, CA (DMT); Divisions of Geriatrics and Clinical Pharmacology, Departments of Medicine and Bioengineering and Therapeutic Sciences, University of California-San Francisco, San Francisco, CA (MB, JBS); Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA (MJP); Department of Sociology, University of California-Los Angeles, Los Angeles, CA (KC); Department of Technology, Operations, and Statistics, Stern School of Business, New York University, New York, NY (JT); Department of Medicine, University of California-San Francisco, San Francisco, CA (AF).
Alicia FernandezFrom the Department of Family Medicine, David Geffen School of Medicine at UCLA, University of California-Los Angeles, Los Angeles, CA (DMT); Divisions of Geriatrics and Clinical Pharmacology, Departments of Medicine and Bioengineering and Therapeutic Sciences, University of California-San Francisco, San Francisco, CA (MB, JBS); Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA (MJP); Department of Sociology, University of California-Los Angeles, Los Angeles, CA (KC); Department of Technology, Operations, and Statistics, Stern School of Business, New York University, New York, NY (JT); Department of Medicine, University of California-San Francisco, San Francisco, CA (AF).
Janice B SchwartzFrom the Department of Family Medicine, David Geffen School of Medicine at UCLA, University of California-Los Angeles, Los Angeles, CA (DMT); Divisions of Geriatrics and Clinical Pharmacology, Departments of Medicine and Bioengineering and Therapeutic Sciences, University of California-San Francisco, San Francisco, CA (MB, JBS); Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA (MJP); Department of Sociology, University of California-Los Angeles, Los Angeles, CA (KC); Department of Technology, Operations, and Statistics, Stern School of Business, New York University, New York, NY (JT); Department of Medicine, University of California-San Francisco, San Francisco, CA (AF).
New York University · USUniversity of California, Los Angeles · USUniversity of California, San Francisco · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Mentoring in the Context of Improving Care for Latinos with DiabetesK24DK102057 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERNANDEZ, ALICIA · 2014 to 2018
$919k
Patient perspectives on primary statin nonadherenceR21AG055832 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TARN, DERJUNG M · 2017 to 2018
$378k
NCATS NIH HHS UL1 TR001881NIA NIH HHS R21 AG055832NIDDK NIH HHS K24 DK102057
6 · The paper itself

Abstract

backgroundDespite emphasis on efforts to prevent cardiovascular disease (CVD), 13% to 34% of people never fill a prescribed statin (primary nonadherence). This study determined perceptions of adults with primary nonadherence to statins.

methodsTen focus groups were conducted with 61 adults reporting primary nonadherence to statins (93% without known CVD). Participants were recruited from an academic medical center and nationwide Internet advertisements.

resultsMajor themes related to primary nonadherence were 1) desire to pursue alternatives before starting a statin (eg, diet and/or exercise, dietary supplements), 2) worry about risks and adverse effects of statins, 3) perceptions of good personal health (suggesting that a statin was not needed), and 4) doubt about the benefits of statins in the absence of disease. Additional themes included mistrust of the pharmaceutical industry, mistrust of prescribing providers, inadequate provider communication about statins, and negative prior experiences with medication. Although rare, a few patients said that high cholesterol does not require treatment if it is genetic. One third noted during focus group discussions that they did not communicate their decision not to take a statin to providers.

conclusionsAdults with primary nonadherence to statins describe seeking alternatives, avoiding perceived risks of statins, poor acceptance/understanding of CVD risk estimates, and doubts about the benefits of statins. Many do not disclose their decisions to providers, thus highlighting the need for provider awareness of the potential for primary nonadherence at the point of prescribing, and the need for future work to develop strategies to identify patients with potential primary nonadherence.

Indexed as

Cardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaHyperlipidemiasAdultHumansMedication AdherencePerceptionHydroxymethylglutaryl-CoA Reductase InhibitorsCardiovascular DiseasesFocus GroupsHypercholesterolemiaHyperlipidemiasMedication AdherenceQualitative ResearchStatins

Identifiers

PMID33452090
PMCPMC8903053
OpenAlexW3120986661

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.